Zelluna ASA Announces Appointment of Geir Christian Melen as New Chief Financial Officer

Core Insights - Zelluna has appointed Geir Christian Melen as the new Chief Financial Officer, effective January 1, 2026, succeeding Hans Vassgård Eid who will step down at the end of December 2025 [1][2][3] Company Overview - Zelluna ASA is a biotechnology company focused on developing allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for cancer treatment [4] - The company's lead program, ZI-MA4-1, targets the MAGE-A4 tumor antigen and is expected to enter clinical trials in 2026 [4] Leadership Transition - Geir Christian Melen has over seven years of experience with Zelluna as Finance Director and possesses a strong understanding of the company's TCR-NK platform and financial strategy [2][3] - The CEO of Zelluna, Namir Hassan, expressed appreciation for Hans Vassgård Eid's contributions, particularly in integrating Zelluna and Ultimovacs and preparing the company for clinical development [2]